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The clinical value of positron emission tomography (PET) using 18F-fluorodeoxyglucose 
(FDG) for follow-up or suspected recurrence of renal cell carcinoma (RCC) has not been 
fully evaluated. The purpose of this study was to assess the diagnostic performance of 
FDG-PET for post-operative assessment in patients with RCC. 
Methods: 
We reviewed 28 scans in 23 patients who had undergone FDG-PET scans after surgery for 
RCC. Diagnostic accuracy of visually interpreted PET was evaluated based on final 
diagnoses obtained histologically or by clinical follow-up at least 6 months. Also, 
additional information over CT, influence on treatment decisions, and the accuracy of FDG 
uptake as a predictor of survival were assessed. 
Results: 
Recurrence of renal carcinoma was histologically (n = 15) or clinically (n=6) confirmed in 
21 of 28 cases. Overall, the sensitivity, specificity, and diagnostic accuracy using 
FDG-PET were 81%, 71%, and 79%, respectively. In papillary RCC, the sensitivity was 
100%; however, that was 75% in clear cell RCC in patient-basis. PET correctly detected 
local recurrence and metastases in all cases in the peritoneum, bone, muscle and adrenal 
gland. Additional information was obtained from scans in 6 cases (21%), which influenced 
4 
therapeutic management in 3 cases (11%). Cumulative survival rates over 5 years in the 
PET-positive vs. the PET-negative group were 46% vs. 83%, respectively (p = 0.17). 
Conclusions: 
FDG-PET would be useful for postoperative surveillance in patients with RCC, although 
its impact on treatment decisions may be limited. Further investigations are necessary to 
conclude whether PET has a prognostic value. 
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Positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) has been 
widely used in clinical oncology as an established modality for imaging cancer. 
FDG-PET is applicable especially for staging or re-staging, and monitoring therapeutic 
response in several cancers. As for renal cell carcinoma (RCC), Wahl et al. reported the 
feasibility of metabolic imaging using FDG, as well as morphological imaging for 
primary and metastatic tumors in their pilot study in 1991 [1], followed by reports 
describing high accuracy of FDG-PET for the diagnosis of RCC [2-4]. Conversely, other 
reports have indicated higher false negative rates [5, 6]. Kang et al. examined 90 PET 
scans in 66 patients, and concluded that the role of FDG-PET in the detection of RCC 
was limited due to its low sensitivity and that, with superior specificity; PET might have 
a complementary role as a problem-solving tool in cases that were equivocal using 
conventional imaging [7]. Thus, the clinical role of FDG-PET for RCC remains 
controversial, but has not been considered helpful for the evaluation of primary RCC. 
Meanwhile, the role of FDG-PET for follow-up or suspected recurrence of RCC has 
been reported to be favorable [8-10]. Clinical courses in patients with recurrent RCC 
following nephrectomy vary, with a survival benefit associated with sufficient 
metastasectomy [11-15]. More accurate diagnosis of recurrent RCC is important, but 
morphological imaging modalities, such as computed tomography (CT), have certain 
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limitations for exact evaluation of recurrent RCC. Hence, metabolic imaging, including 
FDG-PET, is expected demonstrate increased accuracy, but not much has been reported 
yet on the efficacy of PET in the diagnosis of recurrent RCC. 
In the present study, to elucidate the clinical value of FDG-PET for recurrence and 
distant metastases of RCC, we assessed diagnostic performance of FDG-PET for 
post-operative survey in patients with RCC. Furthermore, we assessed whether FDG 
uptake could be a predictor of survival in patients with recurrent RCC. 
 
Patients and methods 
Patients 
Between August 2000 and January 2008, 39 patients underwent 45 FDG-PET scans at 
our institute in order to investigate RCC. Among them, 8 patients (undergoing 8 scans) did 
not histologically prove to have RCC because they didn’t undergo surgery or biopsy, one 
patient (undergoing one scan) had bilateral renal tumors, one of which was not 
histologically proven, and 6 patients (undergoing 7 scans) had synchronous double cancer. 
These patients were excluded in our study. In this retrospective study, we reviewed records 
of 24 patients (18 men, 6 women; age range: 45 – 78 years, mean age: 63 years) who had 
histopathologically proven RCC and did not have synchronous malignant tumors. They 
underwent 29 PET scans. Periods from prior nephrectomy to PET scan ranged from one 
month to 27 years (average: 7.6 years, median: 3.5 years). All cases underwent both PET 
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and CT scans and had prior CT scans. Each scan was performed within 6 months (18 scans 
within a month). All these studies involved daily clinical diagnostic checkups and written 




Fluorine-18 FDG was synthesized by nucleophilic substitution method using an FDG 
synthesizing instrument (F-100, Sumitomo Heavy Industries, Tokyo, Japan) and a 
cyclotron (CYPRIS-325R, Sumitomo Heavy Industries, Tokyo, Japan). For 22 patients (27 
scans) in this study, PET was performed using an Advance scanner (GE Healthcare, 
Milwaukee, WI, USA). For the remaining two patients (2 scans), PET was performed using 
a C-PET plus scanner (ADAC, Philadelphia, PA, USA). After fasting for at least 4 hours, 
patients received intravenous administration of approximately 370 MBq (for the Advance 
scanner) or 130 MBq (for the C-PET plus scanner) of FDG, and whole-body PET images 
were acquired approximately 60 minutes later. Using the Advance scanner, each emission 
scan was obtained for 3 minutes per single bed position and each post-emission 
transmission scan was obtained for 1 minute per single bed position. In order to cover from 
the skull base to the upper thigh, 5 to 6 bed positions were scanned according to the height 
of each patient. Images were acquired in 2-dimensional mode. The ordered subset 
expectation maximization algorithm using 16 subsets, 3 iterations, and a 128 × 128 matrix 
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size reconstructed attenuation-corrected transaxial images. Data acquisition by the C-PET 
plus scanner was performed in 3-dimensional imaging mode with septae in place. 
Following a 56-second transmission scan, a whole body static image was then acquired for 




CT scans were performed prior to PET scans using single or multidetector-row CT 
scanners (Aquillion 8, 16, or 64, Toshiba, Tokyo, Japan; W3000, Hitachi Medico, Tokyo, 
Japan; HiSpeed Advantage, GE Healthcare, Milwaukee, WI, USA). Thoracic and 
abdominal images were obtained separately or continuously with (19 scans) or without (10 
scans) intravenous contrast material. 
 
Image interpretation and analysis 
Interpretations of PET images were performed by consensus of at least two nuclear 
medicine physicians, with all available clinical information, including anatomical 
information provided by prior CT and/or other conventional imaging modalities. In this 
study, interpretation criteria were as follows; lesions were regarded as being an abnormal 
finding or representative of tumor if metabolic activity of FDG was moderately or 
markedly increased, relative to comparable normal structures or surrounding soft tissues. 
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Findings provided by CT images, such as lesion size, shape, or enhancement patterns, were 
not taken into account for the purpose of the study. For example, a lesion with no or faint 
uptake of FDG was regarded as negative even if a recurrent tumor had been suspected by 
CT. Based on these criteria, the diagnostic accuracy of PET was estimated. Final diagnoses 
were made histopathologically or according to clinical follow-up using CT scans for at 
least 6 months. 
When PET detected lesions that had not been observed by conventional imaging 
modalities, or when PET revealed characteristics of lesions other modalities interpreted 
inconclusively, the obtained finding was regarded as ‘additional information’. If patient 
treatments changed as a result of PET findings, these findings were considered to have 
offered ‘clinical impact’. 
Patients were categorized into a PET-positive and a PET-negative group. Kaplan-Meier 
survival estimates were calculated from the first day of the PET scan to death. 
 
Results 
We evaluated a total of 28 PET scans in 23 patients and excluded one patient (using the 
Advance scanner) without definite final diagnosis. The patients' profile and their clinical 
outcome are shown in Table 1. Of 28 cases, 21 were finally confirmed to be in recurrence 
via surgery (n = 7), biopsy (n=8), and clinical follow-up (n = 6), i.e. the tumor had 
increased in size. The remaining seven cases were considered negative for recurrence. 
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Histopathology demonstrated that the type of recurrent cases were clear cell RCC in 16 
patients, papillary RCC in 4 patients, and unknown in one case. 
The PET results were true-positives in 17 cases (clear cell RCC in 12 cases, papillary 
RCC in 4 cases, and unknown histology in 1 case). Fig. 1 demonstrates a true positive case 
which gave additional information and clinical impact. On the other hand, PET failed to 
show recurrent lesions in 4 cases, all of which were clear cell RCC. These missed 
observations included one case of brain and lung metastases, one case of multiple small 
liver metastases, and two cases of metastases to the pancreas. Fig. 2 demonstrates one 
representative false-negative case. PET findings yielded false positive in two cases. One 
case revealed inflammatory changes in the lung and the other, mediastinal lymphadenitis. 
In the remaining 5 cases, the results of PET scans were true negative. As shown in Table 2, 
overall sensitivity, specificity, accuracy, positive predictive value, and negative predictive 
value were 81%, 71%, 79%, 90%, and 56%, respectively. When objects were confined to 
the cases with clinically suspected recurrence by prior CT images or by clinical symptoms, 
such as general malaise or long-lasting fever, the sensitivity, specificity, accuracy, positive 
predictive value, and negative predictive value of PET were 80%, 67%, 78%, 94%, and 
33%, respectively. 
All 4 false-negative cases had clear cell RCC, and the PET results in all 4 cases with 
papillary RCC were true-positive. However, there was no statistically significant difference 
about the diagnostic accuracy between the two histological subtypes according to Fisher’s 
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exact test (p=0.5376). No correlation was found between nuclear grades of primary tumors 
and FDG uptake of recurrent tumors, either.  
PET correctly detected local recurrence, peritoneal dissemination, bone metastases, 
muscle metastases, and adrenal metastases in all cases. On the other hand, sensitivities of 
metastases to the brain, thyroid, liver, or contralateral kidney were low, although the 
number of metastatic lesions was limited (Table 3). Fig. 3 demonstrates a case with 
metastases to the peritoneum and kidney. 
 ‘Additional information’ over CT was obtained in 6 cases (21%). In one patient (No. 1), 
who had been thought to be disease-free by prior unenhanced CT, PET revealed a hilar 
lymph node metastasis which was confirmed histologically. In another patient (No. 17), 
whose prior CT image investigating the cause of general malaise had not shown any 
remarkable findings, PET showed diffuse bone marrow metastases that were later 
biopsy-proven. In Patient No. 20, PET discovered an unknown chest wall metastasis on her 
back, for which excision and irradiation therapy was performed. For these 3 patients, the 
PET findings were considered to yield ‘clinical impacts’. In the remaining 3 patients, PET 
additionally revealed an adrenal gland metastasis, a sternal bone metastasis, and vertebral 
metastases, but their clinical management did not change. 
Among the 23 patients for whom final diagnoses were obtained, one female patient died 
of pneumonia irrelevant to cancer. The survival analysis was, therefore, performed after 
excluding this patient. During their follow-up periods, ranging from 6 to 2691 days with 
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the median of 711 days, nine patients died of primary disease. Of these patients, eight 
belonged to the PET-positive group (16 patients) and one patient, who died of liver failure 
due to multiple liver metastases, belonged to the PET-negative group (6 patients). 
Cumulative survival rates over 5 years in the PET-positive group and in the PET-negative 
group were 46% and 83%, respectively, as presented by Kaplan-Meier survival curves (Fig. 
4). The difference between the two groups did not reach statistical significance according 
to the log-rank test (χ2 = 1.849, p = 0.1739). 
 
Discussion 
The overall diagnostic performance of FDG-PET for recurrent RCC after nephrectomy 
was reasonably high, with a case-based sensitivity of 81%, specificity of 71%, and 
accuracy of 79%, which was considered comparable with those for other malignancies. 
These data indicate that FDG-PET would be a useful tool for postoperative surveillance 
even in patients with RCC. 
The role of FDG-PET for re-staging of RCC was initially examined by Safaei et al, who 
examined 36 patients and demonstrated the sensitivity, specificity, and accuracy of 87%, 
100%, and 89%, respectively [8]. According to published reports, overall sensitivity and 
specificity of FDG-PET for re-staging were 64-87% and 75-100% [8-10]. Our data were 
almost consistent with these observations. As for initial diagnosis and staging of primary 
RCC, overall sensitivity of FDG-PET varied, ranging from 32% to 100% [1-7]. The largest 
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study by Kang et al. showed a sensitivity of 60% [7], raising questions as to the clinical 
value of FDG-PET. FDG-PET may be helpful in the evaluation of recurrent RCC rather 
than in initial staging of RCC. 
In general, there are many RCC that are not FDG-avid, with the reason behind this 
phenomenon remaining unclear. For example, Miyauchi et al. reported that renal cancers in 
their series of 11 patients with newly diagnosed RCC were well visualized with FDG-PET, 
had higher grade, higher glucose transporter-1 (GLUT-1) expression and tended to be 
larger than poorly imaged cancers (Miyauchi T et al., presented at the 1996 annual meeting 
of the Society of Nuclear Medicine). 
In contrast, Miyakata et al. stated that there was no correlation between GLUT-1 
expression and FDG-PET positivity [5]. Montravers et al. formulated the hypothesis that 
mild or absent FDG contrast observed in primary RCC was due to a lack of accessibility of 
radiotracers to tumor cells [3, 16]. 
As compared with primary tumors, it seems that recurrent or metastatic foci of RCC 
tended to be FDG-avid, resulting in higher sensitivity of FDG-PET, although a few 
recurrent tumors were not FDG-avid. In our study, uptake of FDG in recurrent tumors was 
not statistically correlated with histological type, nuclear grade, or presence of sarcomatoid 
components, as is demonstrated in Table 1. This might be because of the small number of 
cases. Further examination with increased number of cases with various histological types 
might be needed. One of the reasons explaining the difference in the diagnostic 
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performance could be attributed to the urinary system. FDG is excreted into urine yielding 
substantial tracer accumulation in a renal collecting system, and thus accumulation in 
primary RCC is sometimes obscured by or misrecognized as excretion itself [2, 8, 17]. 
FDG accumulation in metastatic tumors is not obscured by excretion, except in the 
contralateral kidney. Physiological uptake of FDG in background tissue can mask 
accumulation into tumors in liver, brain, and kidney. In fact, tumors metastasized to these 
organs tended to be missed in our population, although the number of the lesions was 
limited. Nevertheless, as shown in Fig. 3, there was a case in which a metastasis to kidney 
was identified because of FDG uptake in the tumor thrombus directly invading to a renal 
vein that could be easily distinguished from urinary tract. 
Understanding how often additional information is obtained if FDG-PET is used in 
conjunction with morphological information, usually acquired by CT, is important in 
assessing the clinical utility of this technique. In our study, ‘Additional information’ over 
CT was obtained in 6 cases (21%), causing an alteration of therapeutic plans in 3 of these 
cases (11%). Among these cases, two patients (7%) who had been regarded as disease-free 
by prior CT turned out to have recurrence that was detected using PET. However, several 
reports noted that metastasectomy under the appropriate conditions can bring survival 
benefits in selected patients [11-15]. A tumor-free interval of more than 2 years between 
primary tumor and metastasis was reported to be accompanied by a longer disease-specific 
survival after successful metastasectomy [11]. Moreover, molecular-targeted therapies with 
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multi-kinase inhibitors such as sorafenib and sunitinib are now recommended as 
preferential therapy against metastatic RCC. Therefore, it is essential for starting these 
strategies to point out correct metastatic sites. In addition, there are no reliable specific 
tumor markers for RCC, although erythrocyte sedimentation rate (ESR), C-reactive protein 
(CRP), and serum immunosuppressive acidic protein (IAP) have been proposed to be a 
prognostic factor [18-20]. Therefore, the diagnostic imaging for evaluation of recurrence, 
including FDG-PET, may be helpful, even if clinical impacts cannot be obtained very 
frequently. Indeed, although postoperative surveillance is generally performed using CT, 
patients with renal insufficiency after nephrectomy are not permitted to perform CT with 
IV contrast material. CT without IV contrast provides limited information in pointing out 
unexpected metastases. Since renal carcinomas have a tendency to metastasize to a variety 
of organs, it would be difficult to detect metastases to pancreas or muscle only by 
unenhanced CT. Especially in these cases, we believe that FDG-PET (or PET/CT) can be 
effectively applicable. 
In survival time analysis, the PET-positive group tended to have poorer prognosis, but 
the difference of cumulative survival rates between the two groups did not reach statistical 
significance. One of the reasons might be the small number of cases. We need to perform a 
further investigation using an increased number of cases to conclude prognostic value of 
FDG-PET for recurrent RCC. In addition, the kind of adjuvant therapy the patients 
received, or whether metastatic tumors were successfully removed after being found, was 
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not taken into account in the present analysis. Survival curves for both the PET-positive 
and PET-negative group ultimately plateau. This observation may have been affected as a 
result of the removal of metastatic tumors, already being advocated as one independent 
prognostic factor [11-15]. 
The present study had several limitations. This study was not prospective, and the study 
population may have a bias. Clinical follow-up after nephrectomy was usually performed 
using a CT scan, whereas FDG-PET was performed only in limited cases. Indeed, in the 
present study, patients whose prior CT scan suggested presence of recurrent tumors were 
the vast majority, and so the overall prevalence of recurrence in the study was as high as 
75%. If clinical follow-up after nephrectomy had been performed using FDG-PET first, the 
prevalence of recurrence would not have been so high and the diagnostic accuracy might 
have been different. The prior CT scans were not standardized either as enhanced CT or as 
unenhanced CT. FDG-PET/CT is often reported superior to FDG-PET alone. In spite of 
these limitations, we believe that our study could favor the use of FDG-PET for 
postoperative surveillance in patients with RCC, and throughout almost 10 years of our 
institution’s experience, we could undertake to determine whether FDG uptake could be a 
predictor of survival. 
In conclusion, FDG-PET can be a complementary modality for postoperative 
surveillance in patients with RCC. Further investigations are needed to conclude whether 
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Fig. 1—A case of true positive FDG-PET for metastatic renal cell carcinoma with 
additional information and clinical impact. An axial slice of unenhanced CT (a) and an 
axial slice (b) and maximum intensity projection (MIP) image (c) of FDG-PET are shown. 
A 61-year-old male (Pt. #1) respectively had a history of right nephrectomy and 
pulmonary metastasectomy 16 and 3 years earlier. He underwent unenhanced CT and no 
more lesions were found. PET showed significant uptake on the left hilar lymph node 
(arrows), indicating metastasis to the lymph node. Surgical resection was performed, and 
the lesion turned out to be a positive node. 
 
Fig. 2—A case of false negative FDG-PET for metastatic renal cell carcinoma. An axial 
slice of arterial phase of enhanced CT (a) and an axial slice (b) and maximum intensity 
projection image (c) of FDG-PET are shown. A 56-year-old male (Pt. #16) underwent CT 
and was suspected of having metastasis. FDG-PET showed no significant uptake. The 
tumor was resected, and metastasis to the pancreas was histologically confirmed. 
 
Fig. 3—A case with metastatic renal cell carcinoma to the peritoneum, right hilar nodes, 
and left kidney. A maximum intensity projection image of FDG-PET (a) and axial slices 
of enhanced CT (b-d) are demonstrated. Metastatic lesions to the contralateral kidney (a: 
black arrow, b: white arrow) and to the peritoneum (a, d: white arrows) were identified as 
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FDG-avid foci. Tumor thrombus in the left renal vein is also seen on PET and CT (a: 
arrowhead, c: white arrow). 
 
Fig. 4—The overall survival of the PET-positive group including 16 patients (solid line) 
and the PET-negative group including 6 patients (dashed line). The PET-positive group 
tended to have a poorer prognosis, but was not statistically significantly different (p = 
0.1739). 
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Histology of  
prior specimen* 













1 57/M CCC NA NA TP TP Lu Lu Rec. 
 58/M    TN FP (Lu) ‡ None Rec. 
 60/M    TN TN None None Rec. 
 61/M    FN TP LN LN No rec. 
 62/M    TN TN None None No rec. 
2 69/M CCC 1 T3b TN TN None None No rec. 
3 54/M CCC 2 T2a FP FP (LN) ‡ None No rec. 
4 65/M CCC 1 T2b FP TN None None No rec. 
5 76/M CCC 2 T1a TP TP Bo Bo Drop out (rec.) 
 77/M    TP TP Bo Bo, Lu Drop out (rec.) 
6 46/M CCC 3 Tx TP TP 
Ki, LN, 
Pe 
Ki, LN, Pe Death 
7 52/M CCC† 3 M1 TP FN None Br, Lu Rec. 
8 77/M CCC 2 T2 TP TP 
Bo, LN, 
Lu, Mu 




9 62/M CCC† 3 M1 TP TP Lu, Ad Ad, Br, Lu Death 
10 58/M PRC 2 T1a TP TP Pe Pe Death 
11 71/F CCC† 3 T3b TP TP 
Ad, Lo, 
Mu 
Ad, Lo, Mu Death 
12 59/M CCC NA NA TP TP Pa Pa No rec. 
13 58/M CCC† 3 T1b TP FN None Ki, Pa, Thy Rec. 
14 73/F CCC NA NA TP TP Pa Pa No rec. 
15 65/M CCC 1 T2b TP TP Pa Pa Drop out (rec.) 
16 56/M CCC NA T2 TP FN None Pa No rec. 
17 66/M PRC 3 M1 FN TP Bo Bo Death 
18 54/F PRC 3 M1 TP TP 
Ad, Bo, 
Lu 
Ad, Bo, Lu Death 
19 78/M NA 3 T1a TP TP Lu Lu No rec. 
20 45/F PRC 2 T3b TP TP 
Bo, LN, 
Lo, Mu 
Bo, LN, Lo, 
Mu 
Death 
21 56/F CCC NA NA TP FN None Li Death 
22 75/F CCC 2 T1b TN TN None None 
Death from 
pneumonia 
23 64/M CCC 3 M1 TP TP Bo, Li Bo, Li Drop out (rec.) 
Abbreviations: Pt. #, Patient number; F, female; M, male; CCC, Clear cell carcinoma; 
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PRC, Papillary renal cell carcinoma; NA, not available; TP, True positive; TN, True 
negative; FP, False positive; FN, False negative; P/o, Pointed out; Dx, Diagnosis; Ad, 
Adrenal gland; Bo, Bone; Br, Brain; Ki, Contralateral kidney; Li, Liver; LN, Lymph 
node; Lo, Local recurrence; Lu, Lung; Mu, Muscle; Pa, Pancreas; Pe, Peritoneal 
dissemination; Sk, Skin; Thy, Thyroid; Rec., Recurrence. 
* Histological findings are based on the 3rd edition of the General Rule for Clinical and 
Pathological Studies on Renal Cell Carcinoma (in Japanese). 
† With sarcomatoid component. 
‡ False-positive lesion. 
Sites of metastases written in oblique type were biopsy-proven, and sites of metastases 
written in oblique type and underlined were surgically proven. 
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Table 2a. Cross-tabulation of the results of case-based analysis (n = 28) 
 Final diagnosis 
Recurrence (+) Recurrence (-) 
PET Positive 17 2 
Negative 4 5 
Sensitivity 81%, Specificity 71%, Accuracy 79% 
 
Table 2b. Cross-tabulation of the results of cases with suspected recurrence (n = 23) 
 Final diagnosis 
Recurrence (+) Recurrence (-) 
PET Positive 16 1 
Negative 4 2 
Sensitivity 80%, Specificity 67%, Accuracy 78% 
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Table 3. Number of cases according to metastatic foci 
Metastatic organ 
No. of total 
cases 
No. of PET 
true-positive cases 
Lung 7 5 (71.4%) 
Mediastinal lymph node 3 2 (66.6%) 
Abdominal lymph node 2 2 (100%) 
Bone 7 7 (100%) 
Contralateral kidney 2 1 (50%) 
Brain 2 0 (0%) 
Pancreas 5 3 (60%) 
Adrenal gland 3 3 (100%) 
Peritoneal dissemination 2 2 (100%) 
Muscle 3 3 (100%) 
Local recurrence 2 2 (100%) 
Skin 1 0 (0%) 
Liver 2 1 (50%) 
Thyroid 1 0 (0%) 
 
 











